Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,294 shares of the company’s stock, valued at approximately $267,000.

Other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its position in Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Y-mAbs Therapeutics in the third quarter worth about $178,000. Caxton Associates LP purchased a new stake in shares of Y-mAbs Therapeutics in the first quarter worth about $306,000. Price T Rowe Associates Inc. MD grew its holdings in Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares during the period. Finally, XTX Topco Ltd purchased a new position in Y-mAbs Therapeutics during the second quarter valued at approximately $297,000. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $10.56 on Tuesday. The stock’s 50 day simple moving average is $13.69 and its 200-day simple moving average is $12.84. The company has a market cap of $472.98 million, a PE ratio of -19.56 and a beta of 0.68. Y-mAbs Therapeutics, Inc. has a 1-year low of $5.31 and a 1-year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period in the prior year, the company posted ($0.18) earnings per share. On average, equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets cut their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.38.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares in the company, valued at $877,822.57. This represents a 30.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.50% of the stock is owned by corporate insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.